ea0056gp184 | Pituitary / Growth Hormone ' IGF Axis | ECE2018
Peiro I
, Iglesias P
, Simo-Servat A
, Taberna M
, Ruffineli JC
, Guerrero F
, Diez JJ
, Villabona C
Background: Immune checkpoint inhibitors like monoclonal antibodies targeting programmed death 1 receptor (PD1) or its ligand (PD-L1) have shown antitumor activity in many malignancies by enhancing immune response against cancer cells resulting in significant long-lasting responses. However, this therapy can induce endocrine immune-related adverse events (EirAEs). Thyroid dysfunction is a common EirAE, while adrenal insufficiency (AI) is very uncommon.Ob...